MFC Co

MFC Co Financial Leverage

The Financial Leverage (Equity Multiplier) of MFC Co (432980.KQ) as of Nov 18, 2026 is 1.28. In the previous year, Financial Leverage (Equity Multiplier) was 1.54 — a change of -16.39% (lower).

Financial Leverage

1.28

YoY

-16.39%

Last updated:

Financial Leverage (Equity Multiplier) of MFC Co is 2024 1.28 . Financial Leverage (Equity Multiplier) of MFC Co was 2023 1.54 . It decreases by -16.39% lower compared to the previous year.

The MFC Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2022
-14.28 KRW
Jan 1, 2023
1.54 KRW
Jan 1, 2024
1.28 KRW
The MFC Co Financial Leverage history
YEARFinancial LeverageYoY
1.28-16.39%
1.54-110.76%
-14.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MFC Co stock

Financial Leverage (Equity Multiplier) of MFC Co is 1.28 in 2024.

Financial Leverage (Equity Multiplier) of MFC Co changed from 1.54 to 1.28, representing a -16.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) MFC Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s MFC Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — MFC Co

All Key Metrics — MFC Co